Full Press Release Details
Media Release (Code: ASX: PRR; NASDAQ: PBMD)
PRIMA ABSTRACTS ACCEPTED FOR
AT ESMO SYMPOSIUM ON IMMUNO-ONCOLOGY
SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces that an abstract for each of its two
clinical trials for IMP321 has been accepted for Poster presentation (display) during the European Society for Medical Oncology (ESMO) Symposium on Immuno-Oncology Advances in cancer immunotherapy; From vaccines to antibodies and cell
therapies from 4-6 November 2016 in Lausanne, Switzerland.
The abstract titles are:
Both posters will be on display for the duration of the Symposium. The Poster viewing session will
take place over lunch from 13:00-14:15 on Saturday 5 November 2016. The abstracts will also be published in the ESMO Symposium on Immuno-Oncology 2016 Abstract Book, a supplement to the official ESMO journal Annals of Oncology .
For more schedule information see http://www.esmo.org/Conferences/Immuno-Oncology-2016
Prima BioMed is a globally active
biotechnology company that is striving to become a leader in the development of immunotherapeutic products for the treatment of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to
market for patients and to maximise value to shareholders.
Prima s current lead product is IMP321, based on the LAG-3 immune control mechanism which
plays a vital role in the regulation of the T cell immune response. IMP321, which is a soluble LAG-3Ig fusion protein, is an APC activator boosting T cell responses. IMP321 is currently in a Phase II clinical trial as a chemoimmunotherapy for
metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier NCT 02614833) and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT 02676869). A number of additional
LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.
Prima BioMed is listed on the Australian Securities Exchange, and on the NASDAQ in the US. For further
information please visit www.primabiomed.com.au.
For further information please contact:
Australia Investor/Media:
Mr Matthew Gregorowski, Citadel-MAGNUS
Matthew Beck, The Trout Group LLC
Level 12, 95 Pitt Street, Sydney NSW 2000
Phone: +61 2 8315 7003 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889